Adrenomedullin
Sponsors
Kitamura Kazuo, Danish Headache Center, Gruppo Italiano Malattie EMatologiche dell'Adulto, National Cerebral and Cardiovascular Center, Japan, Adrenomed AG
Conditions
Acute Myeloid LeukemiaAdrenomedullinBrain DiseasesCadasilCentral Nervous System DiseasesExperimentele endotoxemie
SepsisHeadache, MigraineMigraine
Phase 2
A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Proof of Concept and Dose-Finding Phase II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of ADRECIZUMAB in Patients with Septic Shock and Elevated Adrenomedullin
Active, not recruitingNL-OMON48885
Start: 2018-03-27Target: 50Updated: 2024-02-28
Adrenomedullin for CADASIL
CompletedNCT06072118
Start: 2022-01-06End: 2023-06-12Updated: 2023-10-10
Unknown Phase
A randomized double-blind placebo-controlled phase I study on the safety, tolerability and pharmacokinetics/-dynamics of escalating single intravenous doses of ADRECIZUMAB (HAM8101) in healthy male subjects during experimental endotoxemia.
Active, not recruitingNL-OMON43006
Start: 2017-01-04Target: 24Updated: 2024-02-28
AM-AF study
Active, not recruitingJPRN-jRCTs071190005
Start: 2019-10-08Target: 16Updated: 2026-06-29
Adrenomedullin Effect on Migraine Without Patients
CompletedNCT04111484
Start: 2019-09-28End: 2020-01-30Updated: 2020-03-02
Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches
Active, not recruitingNCT04460963
Start: 2021-06-09End: 2026-12-01Target: 72Updated: 2026-03-06
Hypersensitivity to Adrenomedullin in Post-Traumatic Headache
RecruitingNCT07059546
Start: 2025-08-01End: 2028-12-01Target: 21Updated: 2025-07-30
Selective Activation of the Adrenomedullin Receptors in Migraine
RecruitingNCT07451769
Start: 2026-03-12End: 2032-12-20Target: 26Updated: 2026-08-28